Eurofins announces its Investment Grade credit rating assigned by Moody’s

Friday, July 24, 2020

Eurofins announces its Investment Grade credit rating assigned by Moody’s

Eurofins Scientific (ERF FP), a global leader in bioanalytical testing, announces today that it has received its first public long-term issuer credit rating by Moody’s Investor Services (“Moody’s”) which assigned an investment grade rating of Baa3 with a stable outlook.

Eurofins has been active in the debt capital markets for many years as one of the major unrated issuers in Europe with a solid track record. With this initial public credit rating, Eurofins should have access to a broader investor base and even better conditions from debt capital markets.

Comment from Moody’s analyst, Perrine Bajolle: “The Baa3 rating assigned to Eurofins reflects the company’s diversified and well-established market position in the bioanalytical testing sector and its track record of gradual operating performance improvement supported by organic and external growth”.

Comment from the CEO, Dr. Gilles Martin: “This credit rating acknowledges Eurofins’ successful growth strategy, its leadership positions in most of its activities and its underlying resilient end-markets. Having just concluded a phase of significant investments, building organically and through acquisitions a global best-in-class laboratories network, Eurofins has reached a size and level of maturity which enables more focus on innovation-fueled organic growth. From this solid base, the Group intends to keep its disciplined financial policy aimed at generating significant value for shareholders while delivering unique solutions for its clients and sustaining revenues, margins and cashflows growth”.

Eurofins Scientific will release its half-year results on 06 August 2020.

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Notes to Editors:

For more information, please visit www.eurofins.com or contact:

About Eurofins – the global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guaranteed for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.